Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Mylan II B.V.
Report date March 23, 2017 · Filed March 24, 2017
Jointly reported with ABBOTT LABORATORIES, Abbott Investments Luxembourg S.A R.L.
Section 16 reporting ended · disclosed 2017-03-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary Shares, nominal value Euro 0.01 per shareSEC Table I · non-derivative | IndirectBy Subsidiaries | 25,750,000 |
Reported balance
After 2017-03-23 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2017-03-23 · Sale · Disposed 44,000,000 · Balance 25,750,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 23, 2017 Filed Mar 24, 2017 11:34 UTC | Mylan II B.V. MYL · Entity 16217 | SaleOrdinary Shares, nominal value Euro 0.01 per share | 44,000,000 | $41.60 | $1,830,400,000.00 |
DisclosureSEC source: 0001104659-17-019006 · a4.xml · nonDerivative · entry 1 ABBOTT LABORATORIES · CIK 0000001800 · 10% owner Abbott Products · CIK 0001650190 · 10% owner Abbott Investments Luxembourg S.A R.L. · CIK 0001635614 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Subsidiaries Disclosed balance after: 25,750,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.